MCID: OCL006
MIFTS: 53

Ocular Hypertension

Categories: Eye diseases, Neuronal diseases

Aliases & Classifications for Ocular Hypertension

MalaCards integrated aliases for Ocular Hypertension:

Name: Ocular Hypertension 12 54 43 15 17 71
Hypertension, Ocular 39

Classifications:



External Ids:

Disease Ontology 12 DOID:9282
ICD9CM 34 365.04
MeSH 43 D009798
NCIt 49 C3285
SNOMED-CT 67 4210003
ICD10 32 H40.05
UMLS 71 C0028840

Summaries for Ocular Hypertension

Disease Ontology : 12 An eye disease that is characterized by elevated intraocular pressure in the absence of optic nerve damage or visual field loss.

MalaCards based summary : Ocular Hypertension, also known as hypertension, ocular, is related to glaucoma, primary open angle and open-angle glaucoma, and has symptoms including eye manifestations An important gene associated with Ocular Hypertension is MYOC (Myocilin), and among its related pathways/superpathways are Cellular Senescence (REACTOME) and p70S6K Signaling. The drugs Ketorolac and Dipivefrin have been mentioned in the context of this disorder. Affiliated tissues include eye, testes and endothelial, and related phenotypes are homeostasis/metabolism and cellular

Wikipedia : 74 Ocular hypertension is the presence of elevated fluid pressure inside the eye (intraocular pressure),... more...

Related Diseases for Ocular Hypertension

Diseases related to Ocular Hypertension via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 204)
# Related Disease Score Top Affiliating Genes
1 glaucoma, primary open angle 32.3 TMCO1 TGFB2 RHO PTGFR OPTN MYOC
2 open-angle glaucoma 31.7 TMCO1 TGFB2 PTGFR OPTN MYOC
3 intraocular pressure quantitative trait locus 31.4 TMCO1 TGFB2 PTGFR OPTN MYOC CA2
4 glaucoma, normal tension 30.7 TMCO1 OPTN MYOC
5 steroid-induced glaucoma 30.5 OPTN NR3C1 MYOC
6 glaucoma-related pigment dispersion syndrome 30.2 TMCO1 OPTN MYOC
7 retinal disease 30.0 RLBP1 RHO OPTN MYOC
8 exudative vitreoretinopathy 1 29.9 RHO EPO AKT1
9 glaucoma 1, open angle, a 29.8 OPTN MYOC
10 eye disease 29.8 TGFB2 RLBP1 RHO OPTN MYOC JUN
11 chronic closed-angle glaucoma 29.8 TGFB2 MYOC
12 acute closed-angle glaucoma 29.5 OPTN MYOC
13 hypertension, essential 29.4 RHOA NR3C1 MTOR JUN HSD11B1 FOS
14 retinitis pigmentosa 28.7 RLBP1 RHOA RHO MYOC MTOR JUN
15 glaucoma 3, primary congenital, a 11.1
16 glaucoma 3, primary infantile, b 11.1
17 hydrophthalmos 11.1
18 yemenite deaf-blind hypopigmentation syndrome 10.5
19 optic nerve disease 10.5
20 uveitis 10.5
21 cataract 10.5
22 solar retinopathy 10.4 RLBP1 RHO
23 peripheral retinal degeneration 10.4 RLBP1 RHO MYOC
24 newfoundland rod-cone dystrophy 10.4 RLBP1 RHO
25 vitreous disease 10.4 TGFB2 RLBP1 RHO
26 fallopian tube serous adenocarcinoma 10.4 RHOA EPO
27 macular retinal edema 10.3
28 vitreoretinopathy, neovascular inflammatory 10.3 TGFB2 RLBP1 FOS
29 myopia 10.3
30 amelogenesis imperfecta, type ig 10.3 JUN FOS AKT1
31 exfoliation syndrome 10.3
32 in situ carcinoma 10.3 NR3C1 FKBP4 AKT1
33 retinal detachment 10.2
34 ocular hyperemia 10.2
35 conjunctivitis 10.2
36 preretinal fibrosis 10.2 TGFB2 RLBP1
37 phacogenic glaucoma 10.2 TMCO1 OPTN MYOC
38 retinal vein occlusion 10.2
39 iridocyclitis 10.2
40 estrogen-receptor positive breast cancer 10.2 MTOR JUN AKT1
41 refractive error 10.2
42 microvascular complications of diabetes 5 10.2
43 primary angle-closure glaucoma 10.2
44 keratitis, hereditary 10.2
45 hydrops, lactic acidosis, and sideroblastic anemia 10.1
46 retinal ischemia 10.1
47 neuropathy 10.1
48 post-traumatic stress disorder 10.1 NR3C1 FOS FKBP5
49 macular degeneration, age-related, 1 10.1
50 allergic conjunctivitis 10.1

Comorbidity relations with Ocular Hypertension via Phenotypic Disease Network (PDN):


Glaucoma, Primary Open Angle

Graphical network of the top 20 diseases related to Ocular Hypertension:



Diseases related to Ocular Hypertension

Symptoms & Phenotypes for Ocular Hypertension

UMLS symptoms related to Ocular Hypertension:


eye manifestations

MGI Mouse Phenotypes related to Ocular Hypertension:

45 (show all 14)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.36 AKT1 CA2 EPO FKBP4 FKBP5 FOS
2 cellular MP:0005384 10.35 AKT1 EPO FKBP4 FOS HSD11B1 JUN
3 growth/size/body region MP:0005378 10.34 AKT1 CA2 FKBP4 FOS HSD11B1 JUN
4 mortality/aging MP:0010768 10.28 AKT1 CA2 EPO FKBP4 FKBP5 FOS
5 endocrine/exocrine gland MP:0005379 10.25 AKT1 CA2 FKBP4 FOS HSD11B1 JUN
6 immune system MP:0005387 10.25 AKT1 CA2 EPO FOS HSD11B1 JUN
7 embryo MP:0005380 10.22 AKT1 EPO FKBP4 FOS JUN MTOR
8 hematopoietic system MP:0005397 10.22 AKT1 EPO FOS HSD11B1 JUN MTOR
9 nervous system MP:0003631 10.18 AKT1 CA2 FOS HSD11B1 JUN MTOR
10 normal MP:0002873 9.96 AKT1 EPO FKBP5 FOS JUN MTOR
11 no phenotypic analysis MP:0003012 9.87 JUN MTOR MYOC NR3C1 OPTN RHO
12 renal/urinary system MP:0005367 9.76 CA2 FKBP4 FKBP5 MTOR NR3C1 RHOA
13 respiratory system MP:0005388 9.56 AKT1 CA2 EPO HSD11B1 JUN MTOR
14 skeleton MP:0005390 9.32 AKT1 CA2 EPO FOS JUN MTOR

Drugs & Therapeutics for Ocular Hypertension

Drugs for Ocular Hypertension (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 140)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
2
Dipivefrin Approved Phase 4 52365-63-6 3105
3
Carteolol Approved Phase 4 51781-06-7 2583
4
Sorbitol Approved Phase 4 50-70-4 5780
5
Loteprednol Approved, Experimental Phase 4 129260-79-3, 82034-46-6 444025 9865442
6
Tobramycin Approved, Investigational Phase 4 32986-56-4 5496 36294
7
Fluticasone Approved, Experimental Phase 4 90566-53-3 62924
8
Clonidine Approved Phase 4 4205-90-7 2803
9
Fluorouracil Approved Phase 4 51-21-8 3385
10
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
11
Brinzolamide Approved Phase 4 138890-62-7 68844
12
Dorzolamide Approved Phase 4 120279-96-1 3154 5284549
13 Ketorolac Tromethamine Phase 4
14 Analgesics Phase 4
15 Sympatholytics Phase 4
16 Immunosuppressive Agents Phase 4
17 Benzalkonium Compounds Phase 4
18 Anti-Infective Agents, Local Phase 4
19 Cathartics Phase 4
20 Laxatives Phase 4
21 Anti-Allergic Agents Phase 4
22 Anesthetics Phase 4
23 Central Nervous System Depressants Phase 4
24 Anti-Asthmatic Agents Phase 4
25 Respiratory System Agents Phase 4
26 Dermatologic Agents Phase 4
27 Bronchodilator Agents Phase 4
28 Mitomycins Phase 4
29 Vitamins Phase 4
30 Anesthetics, Dissociative Phase 4
31 Anesthetics, General Phase 4
32 Anesthetics, Intravenous Phase 4
33 Excitatory Amino Acid Antagonists Phase 4
34 Excitatory Amino Acids Phase 4
35 Pharmaceutical Solutions Phase 4
36 Adrenergic alpha-2 Receptor Agonists Phase 4
37 Adrenergic Agonists Phase 4
38 Brimonidine Tartrate Phase 4 70359-46-5
39 Carbonic Anhydrase Inhibitors Phase 4
40 Brimonidine Tartrate, Timolol Maleate Drug Combination Phase 4
41 Adrenocorticotropic Hormone Phase 4
42 Melanocyte-Stimulating Hormones Phase 4
43 beta-endorphin Phase 4
44
Adenosine Approved, Investigational Phase 3 58-61-7 60961
45
Triamcinolone Approved, Vet_approved Phase 2, Phase 3 124-94-7 31307
46
Betaxolol Approved, Investigational Phase 3 659-18-7, 63659-18-7 2369
47
Bevacizumab Approved, Investigational Phase 2, Phase 3 216974-75-3
48
tannic acid Approved Phase 3 1401-55-4
49
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
50
Apraclonidine Approved Phase 3 66711-21-5 2216

Interventional clinical trials:

(show top 50) (show all 587)
# Name Status NCT ID Phase Drugs
1 A Prospective, Randomized Evaluation of Subjects With Open-angle Glaucoma, Pseudoexfoliative Glaucoma, or Ocular Hypertension Naïve to Medical and Surgical Therapy, Treated With Two Trabecular Micro-bypass Stents (iStent Inject) or Travoprost Ophthalmic Solution 0.004% Unknown status NCT01444040 Phase 4 Travoprost
2 IntraVitreal Triamcinolone Acetonide: Preventing Raised Eye-pressure by Tracking Elevations After Topical Steroids Unknown status NCT00744666 Phase 4 Prednisolone 1% topical eye drops
3 An Open Label,Switch Study of the Safety and Efficacy of Combigan Ophthalmic Solution(Brimonidine 0.2% and Timolol 0.5%)With Latanoprost Compared With Latanoprost Monotherapy in Patient With Glaucoma or Ocular Hypertension. Unknown status NCT00442312 Phase 4 Combigan Ophthalmic Solutiom
4 IOP and Tolerability Study of Preserved Bimatoprost 0.1% or Tafluprost Unit Dose Preservative Free 15microgram/ml, in Patients With OHT or Glaucoma Suitable for Prostaglandin Therapy Unknown status NCT02471105 Phase 4 Preserved Bimatoprost 0.01%;Tafluprost Unit Dose Preservative Free 15microgram/ml
5 A Prospective Evaluation of Open-angle Glaucoma Subjects on Two Topical Hypotensive Medication Treated With One Suprachoroidal Stent Unknown status NCT01252914 Phase 4
6 Safety and Efficacy Assessment of Monoprost® in Comparison With Lumigan® 0.01% and Lumigan® 0.03% Unit Dose, in Patients With Primary Open Angle Glaucoma or Ocular Hypertension, Stabilized by Lumigan® 0.01% With Ocular Surface Intolerance Unknown status NCT02017327 Phase 4 Monoprost;Lumigan 0.01%;Lumigan 0.03% Unit Dose
7 Efficiency of XAL-EASE Device in Glaucoma and/or Ocular Hypertension (OHT) Patients, Treated With Xalatan or Xalacom Unknown status NCT01125306 Phase 4
8 Randomized Crossover Trial Comparing the Hypotensive Effect of Generic Travoprost With That of the Brand Name Travoprost in Patients With Primary Open Angle Glaucoma or Ocular Hypertension Unknown status NCT02796560 Phase 4 Brand name travoprost;Generic travoprost
9 A Prospective, Randomized, Controlled Study to Assess Efficacy,Safety, and Tolerability of Selective Laser Trabeculoplasty vs. Pattern Laser Trabeculoplasty in Patients With Open-angle Glaucoma Unknown status NCT02231515 Phase 4
10 An 8 Week Comparison of Xalatan (Latanoprost) to Apo-latanoprost and Co-latanoprost in the Treatment of Open Angle Glaucoma Unknown status NCT02792803 Phase 4 Xalatan;Apo-Latanoprost;Co-Latanoprost
11 Latanoprost Preserved Versus Unpreserved: Effect on Tear Film Thickness as Measured With OCT Unknown status NCT02585375 Phase 4 Preservative-free latanoprost 50µg/ml;Preserved latanoprost 0.005%
12 A Randomised Controlled Trial to Compare the Clinical Effectiveness of Selective Laser Trabeculoplasty (SLT) Versus Topical Therapy in the Treatment of Pseudoexfoliative Glaucoma Unknown status NCT01704989 Phase 4 Prostagladin
13 A Multiple-Dose Study of the IOP-Lowering Efficacy of Azopt 1.0% Compared to Timolol 0.5% When Added to a PGA as Adjunctive Therapy Over a 24 Hour Period in Patients With Glaucoma or Ocular Hypertension Completed NCT00300079 Phase 4 brinzolamide 1.0%
14 Examination of Ocular Surface Effects With Administration of TRAVATAN Z® and Xalatan® Completed NCT00708422 Phase 4 Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®);Latanoprost ophthalmic solution 0.005% (XALATAN®)
15 A Double-Masked, Placebo-Controlled, Paired Comparison Study of the Mechanism of Action of TRAVATAN 0.004% in Subjects With Glaucoma or Ocular Hypertension Completed NCT00061503 Phase 4 Travoprost
16 A Study of 0.03% Bimatoprost in the Treatment of Primary Open Angle Glaucoma and Ocular Hypertension Completed NCT02020512 Phase 4 0.03% Bimatoprost
17 A Randomized Post-Marketing Efficacy And Safety Study Of Xalatan Compared With "Usual Care" Over 36 Months In Patients With Primary Open-Angle Glaucoma, Exfoliative Glaucoma Or Ocular Hypertension Completed NCT00140062 Phase 4 latanoprost 0.005% (Xalatan)
18 Safety and Efficacy of Brinzolamide Dosed TID With Dorzolamide Dosed TID in Reducing Intraocular Pressure in Patients With Open Angle Glaucoma or Ocular Hypertension Completed NCT00761995 Phase 4 Azopt;Cosopt
19 A Study of Bimatoprost in the Treatment of Primary Open Angle Glaucoma and Ocular Hypertension Completed NCT02061683 Phase 4 Bimatoprost 0.03%
20 A Study of 0.15% Brimonidine Tartrate in Patients With Primary Open Angle Glaucoma and Ocular Hypertension Completed NCT02003534 Phase 4 0.15% Brimonidine Tartrate
21 Comparison of Bimatoprost 0.03% Monotherapy vs. Dual Therapy With Travoprost 0.004% and Timolol 0.5% in Patients With Glaucoma and Ocular Hypertension Completed NCT00348023 Phase 4 Bimatoprost 0.03%, Travoprost 0.004%, Timolol 0.5%
22 A Safety and Efficacy Study of Bimatoprost 0.01% in Primary Open-Angle Glaucoma (POAG) or Ocular Hypertension (OH) Completed NCT01594970 Phase 4 Bimatoprost 0.01%
23 A Multicenter, Open-Label Study To Evaluate The Tolerability Of Preservative Free Dorzolamide-Timolol Therapy In Patients Untreated With Open-Angle Glaucoma Or Ocular Hypertension And Dry Eye(s) Completed NCT00545064 Phase 4 dorzolamide hydrochloride (+) timolol maleate
24 Assessment of Late Day IOP Control in Subjects With Open-Angle Glaucoma or Ocular Hypertension Treated With Travoprost 0.004% (TRAVATAN® Z) or Bimatoprost 0.01% (LUMIGAN®) Completed NCT01464424 Phase 4 Travoprost 0.004% ophthalmic solution;Bimatoprost 0.01% ophthalmic solution
25 Safety and Efficacy of Using the Travoprost/Timolol Fixed Combination (DuoTrav®) in Patients With Open-Angle Glaucoma or Uncontrolled Ocular Hypertension by Beta-blocker Monotherapy (Timolol 0.5%) Completed NCT01336569 Phase 4 Travoprost 0.004%/timolol maleate 0.5% fixed combination
26 Assessing Cosopt Switch Patients Completed NCT00273442 Phase 4 timolol maleate;dorzolamide/timolol maleate fixed combination
27 DuoTrav® Eye Drops As Replacement Therapy Program Completed NCT00828906 Phase 4 DuoTrav
28 24-hour IOP-lowering Effect of Brimonidine 0.1% Completed NCT00457795 Phase 4 brimonidine 0.1% (Alphagan® P)
29 A Single Dose Comfort Comparison of Travatan Z in One Eye Versus Xalatan in the Opposite Eye in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension Completed NCT00527592 Phase 4 Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®);Latanoprost ophthalmic solution 0.005% (XALATAN®)
30 A Prospective, Randomized Evaluation of Subjects With Open-angle Glaucoma, Pseudoexfoliative Glaucoma, or Ocular Hypertension Naïve to Medical and Surgical Therapy, Treated With Two Trabecular Micro-bypass Stents (iStent) or Travoprost Ophthalmic Solution 0.004% Completed NCT01443988 Phase 4 Travoprost
31 Examination of Ocular Surface Effects With Administration of TRAVATAN Z® and XALATAN® Completed NCT00798759 Phase 4 Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®);Latanoprost ophthalmic solution 0.005% (XALATAN®)
32 Pilot Study Comparison of Combigan Two Times Daily (BID) vs Simbrinza Three Times Daily (TID) in Subjects Currently Treated With Latanoprost For Open-Angle Glaucoma or Ocular Hypertension Completed NCT02167035 Phase 4 Combigan Two Times Daily (BID);Simbrinza Three Times Daily (TID)
33 Assessing the Efficacy and Tolerability of AZARGA® (Brinzolamide 1%/Timolol 0.5% Fixed Combination) as Replacement Therapy in Patients on COMBIGAN® (Brimonidine 0.2%/Timolol 0.5% Fixed Combination) Therapy in Canada Completed NCT01415401 Phase 4 Brinzolamide 1% / timolol 0.5% maleate fixed combination
34 Multi-Center Study Comparing Efficacy and Tolerability of TRAVATAN® BAK-free (0.004% Travoprost) in Patients Previously on Latanoprost Ophthalmic Solution 0.005% Monotherapy Completed NCT01510145 Phase 4 Travoprost 0.004% BAK-free
35 Comparing Efficacy and Safety of Combigan With Timolol Adjunctive to Xalatan in Glaucoma or Ocular Hypertension Subjects Completed NCT00735449 Phase 4 Fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5%;timolol maleate 0.5%;latanoprost 0.005%
36 An Evaluation of the Fixed Combination Brimonidine Tartrate 0.2%/ Timolol Maleate 0.5% to Latanoprost 0.005% in Glaucoma or Ocular Hypertension Subjects Completed NCT00811564 Phase 4 fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution;latanoprost 0.005%
37 Prospective, Randomized, Multi-Center Study to Evaluate the Efficacy and Tolerability of DuoTrav® in Patients Previously Uncontrolled on a Beta-blocker Completed NCT02003391 Phase 4 Beta-blocker monotherapy;Travoprost 0.004% / timolol 0.5% fixed combination ophthalmic solution
38 Evaluation of the Safety of GANFORT® (Bimatoprost 0.03% Plus Timolol 0.5%) Ophthalmic Solution in Chinese Patients With Open-angle Glaucoma or Ocular Hypertension Completed NCT02571712 Phase 4 bimatoprost 0.03% plus timolol 0.5%
39 24-Hour Intraocular Pressure (IOP) And Blood Pressure Control In Glaucoma And Ocular Hypertension Patients Completed NCT00330577 Phase 4 timolol maleate 0.5%;latanoprost/timolol fixed combination;placebo (artificial tears)
40 Assessing the Efficacy and Tolerability of TRAVATAN® Solution Without BAK, Containing Polyquad® Preservative (Travoprost 0.004%) Versus LUMIGAN® 0.01% Solution With BAK (Bimatoprost 0.01%) in Treatment Naïve Patients With Ocular Hypertension or Open Angle Glaucoma Completed NCT01664039 Phase 4 Travoprost 0.004% ophthalmic solution;Bimatoprost 0.01% ophthalmic solution
41 Open Multicenter Study on the Efficacy of Xalatan at 3 Months as First-Line Therapy in Naive Patients With Ocular Hypertension (OH) or Open Angle Glaucoma (OAG), Based on Initial Intraocular Pressure (IOP): 20 mmHg Less Than or Equal to IOP Less Than 24 mmHg, IOP Greater Than or Equal to 24 mmHg Completed NCT00647101 Phase 4 Latanoprost
42 Assessing the Efficacy and Tolerability of Changing to DUOTRAV® (Travoprost 0.004%/Timolol 0.5% BAK-Free Fixed Combination), as Replacement Therapy in Patients Previously on Bimatoprost 0.03%/Timolol 0.5% Therapy (Fixed or Unfixed) Completed NCT01327599 Phase 4 Travoprost 0.004%+Timolol 0.5% ophthalmic solution
43 A 2-year, Multicenter, Double-masked, Randomized, Parallel Study of the Safety of LUMIGAN® 0.1 mg/mL Compared With LUMIGAN® 0.3 mg/mL in Patients With Glaucoma or Ocular Hypertension Completed NCT01298700 Phase 4 bimatoprost 0.01% ophthalmic solution;bimatoprost 0.03% ophthalmic solution
44 Safety and Efficacy of Bimatoprost Compared With Latanoprost in Patients With Glaucoma or Ocular Hypertension Completed NCT00541242 Phase 4 bimatoprost 0.03% eye drops;latanoprost 0.005% eye drops
45 Prospective, Randomized, Single-Center Study to Evaluate 24-hour Intraocular Pressure Control With Brinzolamide 1%/Brimonidine 0.2% Fixed Dose Combination Therapy Completed NCT01978600 Phase 4 Brinzolamide 1%/Brimonidine 0.2% ophthalmic suspension;Timolol Maleate 0.5%
46 Patient Preference Comparison of AZARGA Versus COSOPT After Single Doses in Patients With Open-Angled Glaucoma or Ocular Hypertension Completed NCT01471158 Phase 4 Brinzolamide/Timolol Maleate Fixed Combination (AZARGA);Dorzolamide/timolol Maleate Fixed Combination (COSOPT)
47 A Twelve-Week, Double Masked, Parallel Group, Study of Travoprost 0.004% Compared to Timolol 0.5% in Patients With Open-Angle Glaucoma or Ocular Hypertension Completed NCT00763061 Phase 4 Travoprost 0.004% Ophthalmic Solution (Travatan);Timolol 0.5% Ophthalmic Solution (Timoptic)
48 Phase IV Randomised Double-masked Clinical Trial: Assessing Morning Versus Evening Dosing of a Fixed Dose Combination of Travoprost 0.004% / Timolol Maleate 0.5% in Patients With Primary Open-angle Glaucoma or Ocular Hypertension Completed NCT00759239 Phase 4 Travoprost 0.004% / Timolol maleate 0.5%;Travoprost 0.004% / Timolol maleate 0.5%
49 The Efficacy and Safety of Brinzolamide 1%/Timolol 0.5% Fixed Combination Versus Dorzolamide 1%/Timolol 0.5% in Patients With Open-Angle Glaucoma and Ocular Hypertension Completed NCT02325518 Phase 4 Brinzolamide 1%/Timolol maleate 0.5% fixed combination ophthalmic suspension;Dorzolamide hydrochloride 1%/Timolol maleate 0.5% ophthalmic solution;Subject's habitual PGA monotherapy
50 Latanoprost Versus Fotil Completed NCT00304785 Phase 4 latanoprost 0.005%;Fotil;placebo

Search NIH Clinical Center for Ocular Hypertension

Inferred drug relations via UMLS 71 / NDF-RT 50 :


apraclonidine
Apraclonidine hydrochloride
Mannitol
Mannitol hexanitrate
MANNITOL PWDR
Urea
UREA POWDER

Cochrane evidence based reviews: ocular hypertension

Genetic Tests for Ocular Hypertension

Anatomical Context for Ocular Hypertension

MalaCards organs/tissues related to Ocular Hypertension:

40
Eye, Testes, Endothelial, Retina, Thyroid, Bone, Bone Marrow

Publications for Ocular Hypertension

Articles related to Ocular Hypertension:

(show top 50) (show all 4929)
# Title Authors PMID Year
1
Assessment of SNPs associated with the human glucocorticoid receptor in primary open-angle glaucoma and steroid responders. 54 61
20376328 2010
2
Overexpression of myocilin in the Drosophila eye activates the unfolded protein response: implications for glaucoma. 54 61
19148291 2009
3
[Expression of glucocorticoid receptors alpha and beta in mononuclear cells of peripheral blood in patients with glucocorticoid-induced ocular hypertension]. 54 61
19484926 2009
4
Aqueous humor myocilin protein levels in normal, genetic carriers, and glaucoma Beagles. 54 61
18435660 2008
5
Role of MYOC and OPTN sequence variations in Spanish patients with primary open-angle glaucoma. 54 61
17615537 2007
6
The variant N363S of glucocorticoid receptor in steroid-induced ocular hypertension in Hungarian patients treated with photorefractive keratectomy. 54 61
17563720 2007
7
Myocilin-associated exosomes in human ocular samples. 54 61
17094967 2007
8
Coiled-coil targeting of myocilin to intracellular membranes. 54 61
16973161 2006
9
Novel myocilin mutation in a Chinese family with juvenile-onset open-angle glaucoma. 54 61
16401791 2006
10
Characterization of rabbit myocilin: Implications for human myocilin glycosylation and signal peptide usage. 54 61
12697062 2003
11
Myocilin glaucoma. 54 61
12504739 2002
12
Rapid mutation detection by the transgenomic wave analyser DHPLC identifies MYOC mutations in patients with ocular hypertension and/or open angle glaucoma. 54 61
11815346 2002
13
Glucocorticoid induction of the glaucoma gene MYOC in human and monkey trabecular meshwork cells and tissues. 54 61
11431441 2001
14
Evaluation of the myocilin (MYOC) glaucoma gene in monkey and human steroid-induced ocular hypertension. 54 61
11133859 2001
15
Characterization and differential expression of a human gene family of olfactomedin-related proteins. 54 61
11006633 2000
16
Neuronal Epac1 mediates retinal neurodegeneration in mouse models of ocular hypertension. 61
31918438 2020
17
The role of aromatic ring number in phenolic compound-conjugated chitosan injectables for sustained therapeutic antiglaucoma efficacy. 61
31888821 2020
18
How many aqueous humor outflow pathways are there? 61
31622628 2020
19
Review of the measurement and management of 24-hour intraocular pressure in patients with glaucoma. 61
31628907 2020
20
Preservative-free versus preserved brimonidine %0.15 preparations in the treatment of glaucoma and ocular hypertension: short term evaluation of efficacy, safety, and potential advantages. 61
31615279 2020
21
Risk Factors for the Development of Ocular Hypertension After Keratoplasty: A Systematic Review. 61
31764288 2020
22
Hypercapnia augments resistive exercise-induced elevations in intraocular pressure in older individuals. 61
32034962 2020
23
Micropulse transscleral cyclophotocoagulation: initial results using a reduced energy protocol in refractory glaucoma. 61
32036425 2020
24
Mitochondria and Autophagy Dysfunction in Glucocorticoid-Induced Ocular Hypertension/Glaucoma Mice Model. 61
31425668 2020
25
Steroid-induced glaucoma and blindness in vernal keratoconjunctivitis. 61
31055451 2020
26
Electrophysiology in Glaucoma. 61
31809397 2020
27
Early removal of senescent cells protects retinal ganglion cells loss in experimental ocular hypertension. 61
31867890 2020
28
INCIDENCE AND RISK FACTORS FOR HYPOTONY AFTER 25-GAUGE PARS PLANA VITRECTOMY WITH NONEXPANSILE ENDOTAMPONADE. 61
30308563 2020
29
Nuclear factor-kappa beta signaling is required for transforming growth factor Beta-2 induced ocular hypertension. 61
31923415 2020
30
Illness perceptions in people newly diagnosed with glaucoma and ocular hypertension. 61
31079051 2020
31
Second-generation trabecular micro-bypass stent implantation: Retrospective analysis after 12- and 24-month follow-up. 61
31938714 2020
32
Corneal biomechanics and biomechanically corrected intraocular pressure in primary open-angle glaucoma, ocular hypertension and controls. 61
30923134 2020
33
Treatment choices for newly diagnosed primary open angle and ocular hypertension patients. 61
31685971 2020
34
Cataract surgery and intraocular pressure in glaucoma. 61
31688225 2020
35
OCULAR HYPERTENSION AFTER INTRAVITREAL INJECTION OF 2-MG TRIAMCINOLONE. 61
30308561 2020
36
Gene Therapy for Glaucoma by Ciliary Body Aquaporin 1 Disruption Using CRISPR-Cas9. 61
31981492 2020
37
Role of the autotaxin-lysophosphatidic acid axis in glaucoma, aqueous humor drainage and fibrogenic activity. 61
31648019 2020
38
Enriched environment provides neuroprotection against experimental glaucoma. 61
31587281 2020
39
Experimental glaucoma model with controllable intraocular pressure history. 61
31924837 2020
40
[Characteristics and management of Uveitis-Glaucoma-Hyphema syndrome]. 61
31982180 2020
41
Fixed combination netarsudil-latanoprost for the treatment of glaucoma and ocular hypertension. 61
31663782 2020
42
Outcomes of phacoemulsification combined with two iStent inject trabecular microbypass stents with or without endocyclophotocoagulation. 61
31980421 2020
43
Effects of Netarsudil and Latanoprost Alone and in Fixed Combination on Corneal Endothelium and Corneal Thickness: Post-Hoc Analysis of MERCURY-2. 61
31981106 2020
44
Outcome of phacoemulsification in 71 cats: A multicenter retrospective study (2006-2017). 61
31328856 2020
45
Benzoic acid derivative-modified chitosan-g-poly(N-isopropylacrylamide): Methoxylation effects and pharmacological treatments of Glaucoma-related neurodegeneration. 61
31790728 2020
46
ICare Pro: Age Dependent Effect of Central Corneal Thickness on Intraocular Pressure in Glaucoma and Ocular Hypertension Patients. 61
31905299 2020
47
Chronic chorioretinal detachment under normal intraocular pressure in eye with uveitic glaucoma after trabeculectomy: A case report. 61
31914050 2020
48
Outcomes of Gel Stent Implantation for Glaucoma in Patients With Previous Corneal Graft Surgery: A Case Series. 61
31977731 2020
49
Predictors of selective laser trabeculoplasty success in open angle glaucoma or ocular hypertension: does baseline tonography have a predictive role? 61
31988075 2020
50
Long-term Outcomes on de novo Ocular Hypertensive Response to Topical Corticosteroids After Corneal Transplantation. 61
31517723 2020

Variations for Ocular Hypertension

Expression for Ocular Hypertension

Search GEO for disease gene expression data for Ocular Hypertension.

Pathways for Ocular Hypertension

Pathways related to Ocular Hypertension according to GeneCards Suite gene sharing:

(show top 50) (show all 76)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.17 TXN2 MTOR JUN FOS FKBP4 EPO
2
Show member pathways
13.08 TGFB2 RHOA MTOR JUN FOS AKT1
3
Show member pathways
12.86 TGFB2 RHOA MTOR JUN FOS AKT1
4
Show member pathways
12.83 MTOR JUN FOS EPO AKT1
5
Show member pathways
12.8 TGFB2 MTOR JUN FOS AKT1
6
Show member pathways
12.74 RHOA MTOR JUN FOS AKT1
7 12.73 TGFB2 RHOA MTOR JUN FOS EPO
8
Show member pathways
12.64 TGFB2 MTOR JUN FOS AKT1
9
Show member pathways
12.62 RHOA MTOR JUN FOS AKT1
10
Show member pathways
12.62 MTOR JUN FOS FKBP5 FKBP4 AKT1
11
Show member pathways
12.48 RHOA MTOR JUN FOS AKT1
12
Show member pathways
12.45 MTOR JUN FOS AKT1
13 12.45 RHOA JUN FOS AKT1
14
Show member pathways
12.43 RHOA JUN FOS AKT1
15
Show member pathways
12.43 TGFB2 RHOA MTOR JUN FOS
16 12.41 RHOA MTOR JUN AKT1
17 12.37 TGFB2 JUN FOS AKT1
18
Show member pathways
12.36 MTOR JUN FOS AKT1
19 12.36 RHOA JUN FOS AKT1
20
Show member pathways
12.35 MTOR JUN FOS AKT1
21 12.33 TGFB2 RHOA MTOR AKT1
22
Show member pathways
12.3 RHOA NR3C1 MTOR JUN FOS AKT1
23
Show member pathways
12.28 TGFB2 JUN FOS AKT1
24
Show member pathways
12.24 TGFB2 NR3C1 JUN FOS
25
Show member pathways
12.23 RHOA JUN FOS AKT1
26
Show member pathways
12.22 MTOR JUN FOS AKT1
27 12.21 MTOR JUN FOS AKT1
28
Show member pathways
12.19 JUN FOS EPO AKT1
29 12.16 RHO MTOR JUN AKT1
30
Show member pathways
12.15 RHOA JUN FOS AKT1
31 12.11 MTOR JUN FOS AKT1
32
Show member pathways
12.07 MTOR JUN FOS AKT1
33
Show member pathways
12.07 RHOA JUN FOS AKT1
34 12.07 RHOA JUN FOS AKT1
35 12.04 TGFB2 JUN FOS AKT1
36
Show member pathways
12.02 RHOA PTGFR MTOR JUN FOS AKT1
37
Show member pathways
12.01 RHOA MTOR JUN FOS
38 12 RHOA JUN FOS AKT1
39
Show member pathways
11.97 RHOA JUN FOS AKT1
40 11.94 TXN2 RHOA JUN FOS AKT1
41 11.9 MTOR JUN FOS AKT1
42 11.89 TGFB2 JUN FOS
43 11.89 RHOA FOS AKT1
44
Show member pathways
11.85 JUN FOS AKT1
45 11.82 RHOA JUN FKBP4 AKT1
46 11.79 RHOA JUN FOS
47 11.73 RHOA JUN AKT1
48 11.72 RHOA JUN AKT1
49 11.72 NR3C1 JUN FOS AKT1
50
Show member pathways
11.69 NR3C1 JUN FOS

GO Terms for Ocular Hypertension

Cellular components related to Ocular Hypertension according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transcription factor AP-1 complex GO:0035976 8.62 JUN FOS

Biological processes related to Ocular Hypertension according to GeneCards Suite gene sharing:

(show all 25)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 10.01 TGFB2 PTGFR JUN EPO AKT1
2 response to organic substance GO:0010033 9.78 JUN CA2 AKT1
3 aging GO:0007568 9.78 JUN FOS EPO AKT1
4 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.77 TGFB2 MYOC EPO
5 positive regulation of cell growth GO:0030307 9.75 TGFB2 RHOA AKT1
6 positive regulation of endothelial cell proliferation GO:0001938 9.74 MTOR JUN AKT1
7 response to lipopolysaccharide GO:0032496 9.73 PTGFR JUN FOS EPO
8 response to mechanical stimulus GO:0009612 9.72 RHOA JUN FOS
9 SMAD protein signal transduction GO:0060395 9.71 TGFB2 JUN FOS
10 response to hypoxia GO:0001666 9.71 TXN2 TGFB2 RHOA EPO
11 positive regulation of smooth muscle cell proliferation GO:0048661 9.7 MTOR JUN AKT1
12 positive regulation of neuron apoptotic process GO:0043525 9.67 TGFB2 RHOA JUN
13 response to drug GO:0042493 9.65 TXN2 TGFB2 RHOA JUN FOS
14 positive regulation of stress fiber assembly GO:0051496 9.63 RHOA MYOC MTOR
15 cellular response to nutrient levels GO:0031669 9.62 TXN2 MTOR
16 negative regulation of macroautophagy GO:0016242 9.62 MTOR AKT1
17 positive regulation of lipid biosynthetic process GO:0046889 9.6 MTOR AKT1
18 anoikis GO:0043276 9.58 MTOR AKT1
19 regulation of glycogen biosynthetic process GO:0005979 9.56 MTOR AKT1
20 cellular response to reactive oxygen species GO:0034614 9.54 JUN FOS AKT1
21 heart valve morphogenesis GO:0003179 9.51 TGFB2 MTOR
22 cellular response to cadmium ion GO:0071276 9.5 JUN FOS AKT1
23 transforming growth factor beta receptor signaling pathway GO:0007179 9.46 TGFB2 RHOA JUN FOS
24 negative regulation of cell size GO:0045792 9.13 RHOA MTOR AKT1
25 positive regulation of pri-miRNA transcription by RNA polymerase II GO:1902895 8.92 TGFB2 NR3C1 JUN FOS

Molecular functions related to Ocular Hypertension according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 FK506 binding GO:0005528 8.96 FKBP5 FKBP4
2 11-cis retinal binding GO:0005502 8.62 RLBP1 RHO

Sources for Ocular Hypertension

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....